ERBB2 and breast cancer: In addition, HER2 status has a therapeutic impact because monoclonal antibodies against HER2 (Trastuzumab, Pertuzumab, Trastuzumab emtansine) have been shown to be effective for treating HER2-positive breast cancer [4–9].